192 related articles for article (PubMed ID: 24587179)
1. Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell lines.
Spans L; Helsen C; Clinckemalie L; Van den Broeck T; Prekovic S; Joniau S; Lerut E; Claessens F
PLoS One; 2014; 9(2):e90002. PubMed ID: 24587179
[TBL] [Abstract][Full Text] [Related]
2. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel androgen receptor target genes in prostate cancer.
Jariwala U; Prescott J; Jia L; Barski A; Pregizer S; Cogan JP; Arasheben A; Tilley WD; Scher HI; Gerald WL; Buchanan G; Coetzee GA; Frenkel B
Mol Cancer; 2007 Jun; 6():39. PubMed ID: 17553165
[TBL] [Abstract][Full Text] [Related]
4. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
5. Analysis of differentially expressed genes in LNCaP prostate cancer progression model.
Xie BX; Zhang H; Wang J; Pang B; Wu RQ; Qian XL; Yu L; Li SH; Shi QG; Huang CF; Zhou JG
J Androl; 2011; 32(2):170-82. PubMed ID: 20864652
[TBL] [Abstract][Full Text] [Related]
6. NRH:quinone oxidoreductase 2 (NQO2) and glutaminase (GLS) both play a role in large extracellular vesicles (LEV) formation in preclinical LNCaP-C4-2B prostate cancer model of progressive metastasis.
Dorai T; Shah A; Summers F; Mathew R; Huang J; Hsieh TC; Wu JM
Prostate; 2018 Nov; 78(15):1181-1195. PubMed ID: 30009389
[TBL] [Abstract][Full Text] [Related]
7. Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines.
Zayzafoon M; Abdulkadir SA; McDonald JM
J Biol Chem; 2004 Jan; 279(5):3662-70. PubMed ID: 14602722
[TBL] [Abstract][Full Text] [Related]
8. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells.
Wu HC; Hsieh JT; Gleave ME; Brown NM; Pathak S; Chung LW
Int J Cancer; 1994 May; 57(3):406-12. PubMed ID: 8169003
[TBL] [Abstract][Full Text] [Related]
9. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro.
Lin DL; Tarnowski CP; Zhang J; Dai J; Rohn E; Patel AH; Morris MD; Keller ET
Prostate; 2001 May; 47(3):212-21. PubMed ID: 11351351
[TBL] [Abstract][Full Text] [Related]
10. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
[TBL] [Abstract][Full Text] [Related]
11. Osteoblasts produce soluble factors that induce a gene expression pattern in non-metastatic prostate cancer cells, similar to that found in bone metastatic prostate cancer cells.
Fu Z; Dozmorov IM; Keller ET
Prostate; 2002 Apr; 51(1):10-20. PubMed ID: 11920953
[TBL] [Abstract][Full Text] [Related]
12. Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens.
Chen ME; Lin SH; Chung LW; Sikes RA
J Biol Chem; 1998 Jul; 273(28):17618-25. PubMed ID: 9651357
[TBL] [Abstract][Full Text] [Related]
13. Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis.
Rubin J; Chung LW; Fan X; Zhu L; Murphy TC; Nanes MS; Rosen CJ
Prostate; 2004 Jan; 58(1):41-9. PubMed ID: 14673951
[TBL] [Abstract][Full Text] [Related]
14. In vitro the behaviors of metastasis with suppression of VEGF in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line.
Yang L; You S; Kumar V; Zhang C; Cao Y
J Exp Clin Cancer Res; 2012 May; 31(1):40. PubMed ID: 22549243
[TBL] [Abstract][Full Text] [Related]
15. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.
Thalmann GN; Sikes RA; Wu TT; Degeorges A; Chang SM; Ozen M; Pathak S; Chung LW
Prostate; 2000 Jul; 44(2):91-103 Jul 1;44(2). PubMed ID: 10881018
[TBL] [Abstract][Full Text] [Related]
16. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines.
Wu TT; Sikes RA; Cui Q; Thalmann GN; Kao C; Murphy CF; Yang H; Zhau HE; Balian G; Chung LW
Int J Cancer; 1998 Sep; 77(6):887-94. PubMed ID: 9714059
[TBL] [Abstract][Full Text] [Related]
17. Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines.
Trojan L; Schaaf A; Steidler A; Haak M; Thalmann G; Knoll T; Gretz N; Alken P; Michel MS
Anticancer Res; 2005; 25(1A):183-91. PubMed ID: 15816537
[TBL] [Abstract][Full Text] [Related]
18. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis.
Fu Z; Smith PC; Zhang L; Rubin MA; Dunn RL; Yao Z; Keller ET
J Natl Cancer Inst; 2003 Jun; 95(12):878-89. PubMed ID: 12813171
[TBL] [Abstract][Full Text] [Related]
19. 4C-seq revealed long-range interactions of a functional enhancer at the 8q24 prostate cancer risk locus.
Cai M; Kim S; Wang K; Farnham PJ; Coetzee GA; Lu W
Sci Rep; 2016 Mar; 6():22462. PubMed ID: 26934861
[TBL] [Abstract][Full Text] [Related]
20. The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells.
Zhang L; Yang S; Chen X; Stauffer S; Yu F; Lele SM; Fu K; Datta K; Palermo N; Chen Y; Dong J
Mol Cell Biol; 2015 Apr; 35(8):1350-62. PubMed ID: 25645929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
